Treatment of myeloma: Recent developments

Citations of this article
Mendeley users who have this article in their library.
Get full text


Melphalan was the first described treatment for patients with multiple myeloma in the 1960s and is still being used in clinical practice. However, the use of melphalan in combination with prednisone resulted in a median survival of only 2-3 years. Therefore, the dose of melphalan has been intensified since then (140-200 mg/m2). In order to diminish treatment-related morbidity and mortality due to severe myelosuppression induced by these regimens, high-dose melphalan is currently supported with autologous stem cells. Indications for high-dose therapy and the role of further intensification by performing second or allogeneic transplantations are discussed. Furthermore, new therapeutic modalities, such as inhibitors of angiogenesis, also showing direct antiproliferative, cytokine-related and immunomodulatory effects on plasma cells (thalidomide and its newer deratives), inhibitors of the transcription factor NF-κB (proteasome inhibitors) and immunotherapy are described. © 2002 Lippincott Williams & Wilkins.




Zweegman, S., & Huijgens, P. C. (2002). Treatment of myeloma: Recent developments. Anti-Cancer Drugs.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free